Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
KIadis naar de €15,00 in november
Volgen
Mooi bericht van dat koersdoel van eur 19.- met het advies kopen! Ik zie dat het bericht nabeurs 17.55 gekomen is. Zou het wat met de koers doen morgen.....vast niet.
idd leuk bericht... als de koers nu nog naar het koersdoel wil lopen :)
Denk het niet.Is flutaandeel.Kijk naar afgelopen weken.Kijk naar vanmiddag 17.35 uur. Flut.Ongetwijfeld bezig met schitterend produkt maar hebben nog niets en dat vertaalt zich in de koers. Sry voor de believers maar ik heb er inmiddels 3 x mijn neus mee gestoten en wil gewoon even frustratie kwijt.
Dat mag! Het lastige met biotech aandelen is dat de eventuele enorme winst in een paar dagen wordt gemaakt en de rest van de tijd ligt de koers stil. Je weet alleen nooit wanneer de jump is.
Er zullen de komende 12 maanden slechts een beperkt aantal persberichten naar buiten worden gebracht, zoals mogelijk: - updates klinische studies (december 2017, en wellicht ook nog in 2018) - voortgang EMA goedkeuring / in best case resulterend in voorlopige goedkeuring (maart / H2 2018) - voortgang FDA traject (onbekend) - meldingen over samenwerkingen / partnership (onbekend) - wetenschappelijke publicaties (onbekend) - eventuele emissie (H2 2018) Een aantal hiervan kunnen grote invloed op de koers hebben.
geen mogelijkheid om te kopen blijkbaar? of heb ik het verkeerd voor?
je kan niet kopen wanneer je wilt en niet verkopen wanneer je wilt ... bizar
Je wordt gedwongen uit de laat te kopen of hoger. De koers wordt weer netjes vastgezet;-)
Heel apart inderdaad wat er gebeurt nu!!! Heb een order ingelegd op 7,865 en die blijft gewoon open staan terwijl gekocht wordt op 7,862. Broekzak/vestzak verkopen. Deze acties ondersteunen m.i. alleen maar de potentie van dit aandeel.
www.letlifehappen.com/car-t-cell-ther... CAR T-Cell Therapy Is Making Untreatable Cancer Treatable In In The News by Barbara JacobyNovember 10, 20170 Comments 112FacebookTwitterPinterestLinkedIn By: Neel V. Patel From: dailybeast.com Immunotherapy is one of the buzziest words in medicine. Touted as the future for aggressively fighting—maybe even eliminating—diseases, the idea is to jumpstart the patient’s own immune system into better identifying and attacking diseases that normally escape attack and stealthily conquer the body. Alongside immunotherapy is the emergent ability of scientists to genetically modify cells to act in exact ways. What if, now, you could combine the reenergizing powers of immunotherapy with the sharp-shooter specificity of gene therapy? Theoretically, you get treatments that have the astounding potential to make those on the verge of death live. That is, if the treatment doesn’t kill them first. Straddling this balance is chimeric antigen receptor (CAR) T-cell therapy: a revolutionary cancer treatment where doctors take a patient’s own T-cells (which play a significant role in the body’s cell-mediated immune response), genetically reengineer them so they facilitate a more directed and powerful attack against tumor cells, make millions of copies, and infuse them back into the patient so they kill cancerous cells. CAR T-cells have the unique superpower of being able to recognize specific cancer cells with the CAR molecule on their surfaces, said David Porter, an oncologist and cancer researcher based at the University of Pennsylvania. “It essentially reprograms the T-cell so it can now recognize the cancer cell,” he noted. It seems to work phenomenally well. The FDA recently approved two new CAR T-cell therapies: Kymriah, for pediatric and young adults up to age 25 suffering from acute lymphoblastic leukemia (ALL); and Yescarta, for adult patients with certain forms of non-Hodgkin lymphoma—cancers that leave patients with few optimistic options. In Phase II clinical trials assessing the effects of the treatments, Kymriah—which Porter helped create—led to complete cancer remission (i.e., no evidence of the disease) in 83 percent of patients; for Yescarta, complete remission was found in 51 percent of patients. Porter analogizes CARs to velcro: a patient’s own T-cells don’t readily possess the other piece of velcro which will stick to the cancer cell’s velcro. So scientists will change up the T-cell’s genes so they have that velcro. They can now recognize and stick to—and attack—the cancer cells. “This is really like a living drug,” said Porter. “It grows in the body.” One of the most phenomenal aspects is how effective the therapy is in staving off relapse. Once the malignancy is eliminated, there’s a very good chance it stays gone. James Kochenderfer, a scientist at the National Cancer Institute’s Center for Cancer Research who’s worked on Yescarta, and Porter alike note that patients treated as far as six to seven years ago are still in remission. For those patients who are cured, they no longer need any kind of treatment. “After a few weeks in the hospital allowing the T-cells to attack the cancer and contending with the side effects, they exit the treatment ecstatic,” said Kochenderfer. “It’s incredible how well they do, and how much we’ve learned.” But when you take the brakes off the immune system like that, there are potential crashes that threaten to derail the whole thing. A cure for cancer like CAR T-cell therapy is not without its grave safety concerns. Any infection causes the body’s T-cells to activate and release what are called cytokines—signals lead to a rise in body temperature and create other symptoms of illness that are ostensibly meant to help fight off infection. “It’s the same thing when the immune system is fighting cancer,” said Kochenderfer. “Except it’s more intense.” Trials of Yescarta and Kymriah reported some patients experiencing what’s called a cytokine release syndrome (CRS). “It’s like having a really, really severe flu-like syndrome,” said Porter. Fevers can reach a scorching 105 degrees Fahrenheit, create muscle and joint aches, and induce nausea and diarrhea. As CRS progresses, it can lead to dangerously low blood pressure, and life-threatening respiratory problems. Patients with advanced stages of leukemia who are undergoing CAR T-cell therapy are particularly vulnerable to CRS reactions. But there is a way to mitigate CRS: an immunosuppressive medication called Tocilizumab (normally prescribed for rheumatoid arthritis) can block a protein associated with CRS, and shut off the syndrome in practically an hour or two. “It works most of the time,” said Porter, “though I will note it doesn’t work in everybody.” Researchers are still working on tweaking CAR T-cell therapy—perhaps through the dosage, or the product itself—so it won’t lead to a CRS reaction. Kochenderfer emphasizes that one of the most exciting things about this field is the ability to genetically modify the cells in any which way. “In my lab, we’ve made hundreds of different CARs, most of which don’t get into clinical trials. But we can easily change the DNA to change what the CAR can do.” Kochenderfer and his team have already developed a CAR T-cell which produces less cytokine and are currently testing whether it diminishes the chances of CRS reactions in patients. When it comes to genetic engineering, there are endless ways to find a solution—it’s just a matter of proving one works. There are two adjacent issues to safety that CAR T-cell therapy advocates will also need to address as the treatment expands. In a recent Health Affairs article responding to the FDA’s approval of Kymriah, Mildred Solomon, the president of the Hastings Center, and her colleagues argue that problems related to limited patient access and high cost regarding Kymriah (and Yescarta by extension) need resolution. “In both cases, you have what appears to be a highly effective, potential breakthrough treatment,” said Solomon. “They both engender a great deal of excitement about their efficacy”—obtaining FDA approval through expedited pathways. That rapid approval means the treatments need closer monitoring than usual, as well as policy solutions that don’t leave desperate cancer patients out in the cold.None of this detracts from what a mind-blowing success CAR T-cell therapy has been so far. “These kinds of breakthroughs don’t happen that often in medicine and oncology,” said Porter. “Many of these patients that we’ve treated have run out of other treatment options. Many of them have now been cured of incurable cancers. That borders on miraculous.”
NEVDK schreef op 30 november 2017 09:16 :
je kan niet kopen wanneer je wilt en niet verkopen wanneer je wilt ... bizar
Dit is geen aandeel om in te gaan zitten handelen. Bied en laat liggen vaak ver uiteen. Het is een aandeel om een bescheiden positie op de plank te leggen?
CAR T-Cell Therapy Brings New Hope to Cancer Patients at Stanford Health Care 11.29.2017 Select patients with a certain type of blood cancer now have access to CAR T-cell therapy at Stanford. Using a revolutionary new treatment option, Stanford Health Care is now treating certain blood cancers in patients who have failed to improve with chemotherapy, radiation therapy, or stem cell transplant. Called CAR T-cell therapy, the treatment involves removing immune cells from the patient’s blood, engineering them in a laboratory to improve their cancer-fighting power, then reinfusing them into the patient. The technique is giving hope to people who had been told they were running out of options. “It’s exceeding anything I could ever have imagined two years ago,” said David Miklos, MD, PhD, associate professor of medicine at the Stanford University School of Medicine and CAR T-cell therapy expert at Stanford Health Care. “We hijack the patient’s T cells, making a chimeric molecule.” Just last month, a new CAR T-cell therapy was approved by the FDA and is now available to select patients with a certain type of hematologic cancer. Stanford Health Care is the only Northern California health system to offer the treatment. CAR T-cell therapy, a form of immunotherapy, is a relatively new weapon against cancer. Physicians have known that our immune systems protect us against cancer, but until recently didn’t know how to employ that knowledge. With CAR T-cell therapy, clinicians remove T cells, a kind of white blood cell, from the patient. In a laboratory, they then manipulate the cells with a virus that causes them to produce chimeric antigen receptors, or CARs, which in turn attack the tumor cells. “We supercharge the immune system,” Miklos said, adding that the engineered cells stay in the body, fighting cancer “potentially forever.” Meanwhile, the patient undergoes chemotherapy to reduce the white blood cell count, which encourages the T cells, once reinfused, to multiply. Nine days after the T cells are removed, the patient receives the infusion. Within a week, the engineered cells increase from 2 million to 20 billion and begin attacking the cancer. During the infusion and for several days afterward, patients stay in the hospital so they can be monitored for side effects. Most patients experience what feels like a severe flu — a sign that their immune systems are revving up. Some also develop neurotoxicity, which can affect mental functioning. To treat these conditions, physicians slow down the expansion of the CAR T cells. Physicians are currently using CAR T-cell therapy to treat diffuse large B-cell lymphoma and acute lymphoblastic leukemia. Miklos said they hope to treat other forms of cancer, eventually even solid tumors such as those found in breast and lung cancer, in the near future.Only patients who have failed to improve after traditional cancer treatments are receiving the therapy for now, but Miklos said the goal is to find treatments that can replace chemotherapy. “Imagine that this is the beginning of no longer depending on chemo for treating patients,” he said. “It’s a game changer.”
Chiddix schreef op 30 november 2017 09:49 :
[...]
Dit is geen aandeel om in te gaan zitten handelen. Bied en laat liggen vaak ver uiteen. Het is een aandeel om een bescheiden positie op de plank te leggen?
Zit er niet in voor KT. 40% van mijn port. Ik geef het aandeel tot juni-juli volgend jaar en dan alles weg. Dan te gevaarlijk voor verdere verwatering. Ik wou een klein stuk verkopen om in een ander biotech aandeel mijn gemidd te verlagen...
NEVDK schreef op 30 november 2017 10:23 :
[...]
Zit er niet in voor KT. 40% van mijn port. Ik geef het aandeel tot juni-juli volgend jaar en dan alles weg. Dan te gevaarlijk voor verdere verwatering.
Ik wou een klein stuk verkopen om in een ander biotech aandeel mijn gemidd te verlagen...
Bij biotechaandelen die met hun medicatie nog niet door de keuring zijn gekomen. moet je een engelengeduld hebben. De keuring is pas over 7-9 maanden. Mocht de EMA het toelaten, duurt het nog wel even voor het middel ingezet wordt(2019). Daarvoor krijg je nog een emissie of bod van farmaceut. Een bod voordat er gekeurd wordt is mogelijk maar daar moet je niet van uitgaan.
Het kan heel snel gaan, als er flink gekocht gaat worden, staat het zo op 11 euro. Daar heb ik nog op gekocht, een paar weken geleden.
Er gaat echt niemand, zonder dat er een nieuwsmelding is gedaan, 11 euro bieden voor deze aandelen. Koers staat dichter bij 1,50 dan bij de 15,0.
Na belangrijk nieuws stijgt de koers erg hard en wordt een bieding alleen maar duurder. Ik verwacht eigenlijk ook geen overname, maar Kiadis sluit mi. niets uit, en uiteindelijk is alles te koop! Mijn indruk is dat Kiadis internationaal goed bekend is, en de verdere ontwikkelingen m.b.t. Atir101 worden nauwgezet gevolgd. Zodra er ook maar iets aan duidelijkheid komt, wordt het stijgingspotentieel zichtbaar. Wat wel herkenbaar is bij aandelen die niet veel fluctueren (zoals Kiadis) er velen negatief lijken te worden. Blijkbaar zitten hier ook korte termijn beleggers, de vraag is of Kiadis dan een goed fonds is, dan moet je wel heel goed kunnen timen, en dat kan helemaal niemand, zelfs Warren Buffet niet.
Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows' Michela Tindera , FORBES STAFF 30 november 2017 www.forbes.com/sites/michelatindera/2... Johnny Wolf Incoming Novartis CEO Vas Narasimhan at the Forbes Healthcare Summit in New York City in November 30, 2017. Incoming CEO at Swiss drugmaker Novartis , Vas Narasimhan, said he isn’t interested in following the herd in drug development. “How do you make smart contrarian bets?” Narasimhan said of his strategy for Novartis Wednesday at the Forbes Healthcare Summit in New York City. Narasimhan, who is the current chief medical officer and head of global drug development at Novartis, will take over for current CEO Joe Jimenez in February. Novartis’ latest historic bet on cancer therapy Kymriah has made waves throughout the industry. Approved by the Food and Drug Administration in August for use on children with acute lymphoblastic leukemia, it is a novel therapy called a chimeric antigen receptor T-cell, or CAR-T that genetically modifies a patient’s own white blood cells, training them to essentially hunt down and kill tumors. “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” FDA Commissioner Scott Gottlieb said in a statement in August when Kymriah was approved. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.” While its implications are vast, the therapy does not come cheap. It’s list price is $475,000 per patient. “There’s no question that the list price raises eyebrows,” Narasimhan said. “We need to price our drugs at a cost-effective level that is acceptable for society,” he expanded. “[Value-based pricing model] is something we have to grapple with. We need to come up with different models for different medicines.” FORBES reported in October that Novartis has said it's offering insurance companies a value-based pricing structure where it only pays for patients who enter remission within three months. Johnny Wolf Austin Schuetz, one of the first patients to benefit from Novartis' CAR-T treatment, on stage at the Forbes Healthcare Summit with Leukemia & Lymphoma Society president and CEO Louis DeGennaro. One of the earliest beneficiaries of this therapy was 10-year-old Austin Schuetz. Shortly before his 3rd birthday he and his parents were given a devastating diagnosis, acute lymphoblastic lymphoma. Over the next few years of his treatment, which included chemotherapy, radiation and a bone marrow transplant, he continued to have relapses until his parents, Kimberly and Jeffrey Schuetz, learned of Novartis' phase one clinical trial for Kymriah. Austin was eligible and he enrolled soon after in 2013. “We would just kind of wait in the wings, and hope was all we had,” Kimberly Schuetz said at the Summit. Today, Austin, who joined his parents on stage at the Summit, is healthy thanks to the therapy. “That’s what made me want to join the industry and certainly what motivates me every day,” Narasimhan said. “If we can solve puzzles that biology gives us and change patients lives.”
Denk dat deze hier ook wel thuis hoort. Komt van het Pharming forum, maar voor Kiadis is dit wereldnieuws :-) FDA Aims to Expand Early-Approval Program for Promising Drugs By Anna Edney November 30, 2017, 7:28 AM PST Commissioner proposes approval based on early, small trials Scott Gottlieb speaks before House subcommittee on health The Food and Drug Administration wants to help patients get faster access to promising cancer treatments. The agency is preparing proposals that would expand an accelerated-approval program for lifesaving medications, FDA Commissioner Scott Gottlieb told House lawmakers on Thursday. Drugmakers can seek rapid conditional approval for treatments for cancer or other serious diseases based on evidence that a drug is likely to extend patient survival. Later trials once such a drug is on the market are necessary to prove the survival benefit. The FDA is now looking at ways to conditionally approve an experimental drug if it shows increased survival in early trials in a small number of patients, Gottlieb said. Typically, early trials are used to determine how best to craft larger studies and aren’t used for approval. But Gottlieb wants early trials to be used for approval if they show an outsized survival benefit. Any drug cleared based on early-trial data would later have to be proven in larger trials to maintain the benefit. Gottlieb was speaking before the House Energy and Commerce Committee’s health panel on the FDA’s implementation of the 21st Century Cures Act, a bill passed last year that is meant to accelerate development of new pharmaceuticals. The commissioner has also tried to boost competition and ease drug development in an effort to lower prices. Earlier this year, the FDA said it would update policies to help drugmakers gain approval of treatments targeting specific gene mutations that can spur tumors. Makers of cancer drugs are increasingly embracing such genetic therapies, compared to the traditional manner of identifying cancers by the affected body part, such as the lung, breast or kidney.www.bloomberg.com/news/articles/2017-...
De biotechnologie index in de USA heeft het de afgelopen vier weken niet echt goed gedaan, maar vandaag stijgt deze met bijna 2%. Mogelijk kan Kiadis morgen op deze golf mee.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,79
+0,96%
EUR/USD
1,0710
+0,07%
FTSE 100
8.044,81
+0,26%
Germany40^
18.161,70
+0,13%
Gold spot
2.319,81
-0,10%
NY-Nasdaq Composite
15.696,64
+1,59%
Stijgers
Dalers